This page shows the latest AUTO1 news and features for those working in and with pharma, biotech and healthcare.
It is earmarking $125m to continue the clinical development of its pipeline, headed by CD19-targeted CAR-T therapy AUTO1 in adult acute lymphoblastic leukaemia (ALL) – a rival to Novartis’ ... Autolus is planning a pivotal trial of AUTO1, which it
Autolus is hoping that AUTO1 will change that, and its first wave of data from that programme found it compared favourably to other CAR-T therapies in adult ALL. ... For comparison purposes, Yescarta also had a 23% severe CRS rate, and a 39% grade 3
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...